Compounds to treat Alzheimer's disease
First Claim
Patent Images
1. A substituted amine of formula (XV) or a salt thereof, where R1 is —
- (CH2)n1—
(R1-aryl) where n1 is zero or one and where R1-aryl is phenyl, optionally substituted with one, two, or three of the following substituents (A) C1-C6 alkyl optionally substituted with one, two or three substituents selected from the group consisting of C1-C3 alkyl, —
F, —
Cl, —
Br, —
I, —
OH, —
SH, —
C≡
N, —
CF3, C1-C3 alkoxy, and —
NR1-aR1-b where R1-a and R1-b —
H or C1-C6 alkyl, (D) —
F, Cl, —
Br or —
I, (F) —
C1-C6 alkoxy optionally substituted with one, two, or three of;
—
F, (G) —
NRN-2RN-3 where RN-2 and RN-3 are as defined below, (H) —
OH, (I) —
C≡
N, (K) —
CO—
(C1-C4 alkyl), where R2 is;
—
H, or C1-C3 alkyl;
where R3 is;
—
H or C1-C3 alkyl;
where RN is RN-1—
XN—
where XN is selected from the group consisting of;
(A) —
CO—
, (B) —
SO2—
, (C) —
(CR′
R″
)1-6 where R′ and
R″
are the same or different and are —
H or C1-C4 alkyl, (E) a single bond;
where RN-1 is RN-aryl where RN-aryl is phenyl, 1-naphthyl, or 2-naphthyl, each of which is optionally substituted with one, two or three of the following substituents which can be the same or different and are;
(1) C1-C6 alkyl, optionally substituted with one, two or three substituents selected from the group consisting of C1-C3 alkyl, —
F, —
Cl, —
Br, —
I, —
OH, —
SH, —
C≡
N, —
CF3, C1-C3 alkoxy, and —
NR1-aR1-b where R1-a and R1-b are as defined above, (2) —
OH, (3) —
NO2, (4) —
F, —
Cl, —
Br, or —
I, (5) —
CO—
OH, (6) —
C≡
N, (7) —
(CH2)0-4—
CO—
NRN-2RN-3 where RN-2 and RN-3 are the same or different and are selected from the group consisting of;
(a) —
H, (b) —
C1-C6 alkyl optionally substituted with one substitutent selected from the group consisting of;
(i) —
OH, and (ii) —
NH2, (c) —
C1-C6 alkyl optionally substituted with one to three —
F, —
Cl, —
Br, or —
I, (d) —
C3-C7 cycloalkyl, (e) —
(C1-C2 alkyl)-(C3-C7 cycloalkyl), (f) —
(C1-C6 alkyl)-O—
(C1-C3 alkyl), (8) —
(CH2)0-4—
CO—
(C1-C12 alkyl), (11) —
(CH2)0-4—
CO—
(C3-C7 cycloalkyl), (15) —
(CH2)0-4—
CO—
RN-4 where RN-4 is selected from the group consisting of morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, homomorpholinyl, homothiomorpholinyl, homothiomorpholinyl S-oxide, homothiomorpholinyl S,S-dioxide, pyrrolinyl and pyrrolidinyl where each group is optionally substituted with one, two, three, or four of C1-C6 alkyl, (16) —
(CH2)0-4—
CO—
O—
RN-5 where RN-5 is selected from the group consisting of;
(a) C1-C6 alkyl, (b) —
(CH2)0-2—
(R1-aryl) where R1-aryl is as defined above, (e) C3-C7 cycloalkyl, and (21) —
(CH2)0-4—
N(H or RN-5)—
CO—
O—
RN-5 where RN-5 can be the same or different (24) —
(CH2)0-4—
N(—
H or RN-5)—
CO—
RN-2 where RN-5 and RN-2 can be the same or different, (25) —
(CH2)0-4—
NRN-2RN-3 where RN-2 and RN-3 can be the same or different, (26) —
(CH2)0-4—
RN-4, (27) —
(CH2)0-4—
O—
CO—
(C1-C6 alkyl), (29) —
(CH2)0-4—
O—
CO—
N(RN-5)2, (31) —
(CH2)0-4—
O—
(RN-5)2 (34) —
(CH2)0-4—
O—
(C1-C6 alkyl optionally substituted with one, two, three, four, or five —
F), (35) C3-C7 cycloalkyl, (39) —
(CH2)0-4—
C3-C7 cycloalkyl, where RA is;
(I) —
C1-C10 alkyl optionally substituted with one, two or three substituents selected from the group consisting of C1-C3 alkyl, —
F, —
Cl, —
Br, —
I, —
OH, —
SH, —
C≡
N, —
CF3, C1-C6 alkoxy, —
O-phenyl, —
NR1-aR1-b where R1-a and R1-b are as defined above, —
OC═
O NR1-aR1-b where R1-a and R1-b are as defined above, —
S(═
O)0-2 R1-a where R1-a is as defined above, —
NR1-aC═
O NR1-aR1-b where R1-a and R1-b are as defined above, —
C═
O NR1-aR1-b where R1-a and R1-b are as defined above, and —
S(═
O)2 NR1-aR1-b where R1-a and R1-b are as defined above, (III) —
(CRA-xRA-y)0-4—
RA-aryl where RA-x and RA-y are (A) —
H, (B) C1-C4 alkyl optionally substituted with one or two —
OH, (C) C1-C4 alkoxy optionally substituted with one, two, or three of;
—
F, (D) —
(CH2)0-4—
C3-C7 cycloalkyl, (E) C2-C6 alkenyl containing one or two double bonds, (F) C2-C6 alkynyl containing one or two triple bonds, (G) phenyl, (IV) -cyclopentyl, -cyclohexyl, or -cycloheptyl ring fused to RA-aryl, where RA-aryl is as defined above where one carbon of cyclopentyl, cyclohexyl, or -cycloheptyl is optionally replaced with NH, NRN-5, O, or S(═
O)0-2, and where cyclopentyl, cyclohexyl, or -cycloheptyl can be optionally substituted with one or two —
C1-C3 alkyl, —
F, —
OH, —
SH, —
C≡
N, —
CF3, C1-C6 alkoxy, ═
O, or —
NR1-aR1-b where R1-a and R1-b are as defined above, (VI) —
H, (VII) —
C═
OR7, wherein R7 is;
C1-C6 alkyl, phenyl, (aryl)alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, haloalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, lower alkenyl, where X is —
N, or —
O, with the proviso that when X is O, RB is absent;
and when X is N, RB is;
—
C1-C10 alkyl optionally substituted with one, two or three substituents selected from the group consisting of C1-C3 alkyl, —
F, —
Cl, —
Br, —
I, —
OH, —
SH, —
C≡
N, CF3, C1-C6 alkoxy, —
O-phenyl, —
NR1-aR1-b —
OC═
O NR1-aR1-b —
C═
O NR1-aR1-b where R1-a and R1-b are as defined above, and S(═
O)2 NR1-aR1-b;
(II) —
(CH2)0-3—
(C3-C8) cycloalkyl where cycloalkyl can be optionally substituted with one, two or three substituents selected from the group consisting of C1-C3 alkyl, —
F, —
Cl, —
Br, —
I, —
OH, —
SH, —
C≡
N, —
CF3, C1-C6 alkoxy, —
O-phenyl, —
CO—
OH, —
CO—
O—
(C1-C4 alkyl), and NR1-aR1-b;
or —
H.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention is substituted amines of formula (XV)
useful in treating Alzheimer'"'"'s disease and other similar diseases.
-
Citations
45 Claims
-
1. A substituted amine of formula (XV)
or a salt thereof, where R1 is — - (CH2)n1—
(R1-aryl) where n1 is zero or one and where R1-aryl is phenyl, optionally substituted with one, two, or three of the following substituents(A) C1-C6 alkyl optionally substituted with one, two or three substituents selected from the group consisting of C1-C3 alkyl, —
F, —
Cl, —
Br, —
I, —
OH, —
SH, —
C≡
N, —
CF3, C1-C3 alkoxy, and —
NR1-aR1-b where R1-a and R1-b —
H or C1-C6 alkyl,(D) —
F, Cl, —
Br or —
I,(F) —
C1-C6 alkoxy optionally substituted with one, two, or three of;
—
F,(G) —
NRN-2RN-3 where RN-2 and RN-3 are as defined below,(H) —
OH,(I) —
C≡
N,(K) —
CO—
(C1-C4 alkyl),where R2 is;
—
H, or C1-C3 alkyl;
where R3 is;
—
H or C1-C3 alkyl;
where RN is RN-1—
XN—
where XN is selected from the group consisting of;
(A) —
CO—
,(B) —
SO2—
,(C) —
(CR′
R″
)1-6 where R′ and
R″
are the same or different and are —
H or C1-C4 alkyl,(E) a single bond;
where RN-1 is RN-aryl where RN-aryl is phenyl, 1-naphthyl, or 2-naphthyl, each of which is optionally substituted with one, two or three of the following substituents which can be the same or different and are;
(1) C1-C6 alkyl, optionally substituted with one, two or three substituents selected from the group consisting of C1-C3 alkyl, —
F, —
Cl, —
Br, —
I, —
OH, —
SH, —
C≡
N, —
CF3, C1-C3 alkoxy, and —
NR1-aR1-b where R1-a and R1-b are as defined above,(2) —
OH,(3) —
NO2,(4) —
F, —
Cl, —
Br, or —
I,(5) —
CO—
OH,(6) —
C≡
N,(7) —
(CH2)0-4—
CO—
NRN-2RN-3 where RN-2 and RN-3 are the same or different and are selected from the group consisting of;
(a) —
H,(b) —
C1-C6 alkyl optionally substituted with one substitutent selected from the group consisting of;
(i) —
OH, and(ii) —
NH2,(c) —
C1-C6 alkyl optionally substituted with one to three —
F, —
Cl, —
Br, or —
I,(d) —
C3-C7 cycloalkyl,(e) —
(C1-C2 alkyl)-(C3-C7 cycloalkyl),(f) —
(C1-C6 alkyl)-O—
(C1-C3 alkyl),(8) —
(CH2)0-4—
CO—
(C1-C12 alkyl),(11) —
(CH2)0-4—
CO—
(C3-C7 cycloalkyl),(15) —
(CH2)0-4—
CO—
RN-4 where RN-4 is selected from the group consisting of morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, homomorpholinyl, homothiomorpholinyl, homothiomorpholinyl S-oxide, homothiomorpholinyl S,S-dioxide, pyrrolinyl and pyrrolidinyl where each group is optionally substituted with one, two, three, or four of C1-C6 alkyl,(16) —
(CH2)0-4—
CO—
O—
RN-5 where RN-5 is selected from the group consisting of;
(a) C1-C6 alkyl, (b) —
(CH2)0-2—
(R1-aryl) where R1-aryl is as defined above,(e) C3-C7 cycloalkyl, and (21) —
(CH2)0-4—
N(H or RN-5)—
CO—
O—
RN-5 where RN-5 can be the same or different(24) —
(CH2)0-4—
N(—
H or RN-5)—
CO—
RN-2 where RN-5 and RN-2 can be the same or different,(25) —
(CH2)0-4—
NRN-2RN-3 where RN-2 and RN-3 can be the same or different,(26) —
(CH2)0-4—
RN-4,(27) —
(CH2)0-4—
O—
CO—
(C1-C6 alkyl),(29) —
(CH2)0-4—
O—
CO—
N(RN-5)2,(31) —
(CH2)0-4—
O—
(RN-5)2(34) —
(CH2)0-4—
O—
(C1-C6 alkyl optionally substituted with one, two, three, four, or five —
F),(35) C3-C7 cycloalkyl, (39) —
(CH2)0-4—
C3-C7 cycloalkyl,where RA is;
(I) —
C1-C10 alkyl optionally substituted with one, two or three substituents selected from the group consisting of C1-C3 alkyl, —
F, —
Cl, —
Br, —
I, —
OH, —
SH, —
C≡
N, —
CF3, C1-C6 alkoxy, —
O-phenyl, —
NR1-aR1-b where R1-a and R1-b are as defined above, —
OC═
O NR1-aR1-b where R1-a and R1-b are as defined above, —
S(═
O)0-2 R1-a where R1-a is as defined above, —
NR1-aC═
O NR1-aR1-b where R1-a and R1-b are as defined above, —
C═
O NR1-aR1-b where R1-a and R1-b are as defined above, and —
S(═
O)2 NR1-aR1-b where R1-a and R1-b are as defined above,(III) —
(CRA-xRA-y)0-4—
RA-aryl where RA-x and RA-y are(A) —
H,(B) C1-C4 alkyl optionally substituted with one or two —
OH,(C) C1-C4 alkoxy optionally substituted with one, two, or three of;
—
F,(D) —
(CH2)0-4—
C3-C7 cycloalkyl,(E) C2-C6 alkenyl containing one or two double bonds, (F) C2-C6 alkynyl containing one or two triple bonds, (G) phenyl, (IV) -cyclopentyl, -cyclohexyl, or -cycloheptyl ring fused to RA-aryl, where RA-aryl is as defined above where one carbon of cyclopentyl, cyclohexyl, or -cycloheptyl is optionally replaced with NH, NRN-5, O, or S(═
O)0-2, and where cyclopentyl, cyclohexyl, or -cycloheptyl can be optionally substituted with one or two —
C1-C3 alkyl, —
F, —
OH, —
SH, —
C≡
N, —
CF3, C1-C6 alkoxy, ═
O, or —
NR1-aR1-b where R1-a and R1-b are as defined above,(VI) —
H,(VII) —
C═
OR7,wherein R7 is;
C1-C6 alkyl, phenyl, (aryl)alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, haloalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, lower alkenyl, where X is —
N, or —
O, with the proviso that when X is O, RB is absent;
and when X is N, RB is;
—
C1-C10 alkyl optionally substituted with one, two or three substituents selected from the group consisting of C1-C3 alkyl, —
F, —
Cl, —
Br, —
I, —
OH, —
SH, —
C≡
N, CF3, C1-C6 alkoxy, —
O-phenyl, —
NR1-aR1-b —
OC═
O NR1-aR1-b —
C═
O NR1-aR1-b where R1-a and R1-b are as defined above, and S(═
O)2 NR1-aR1-b;
(II) —
(CH2)0-3—
(C3-C8) cycloalkyl where cycloalkyl can be optionally substituted with one, two or three substituents selected from the group consisting of C1-C3 alkyl, —
F, —
Cl, —
Br, —
I, —
OH, —
SH, —
C≡
N, —
CF3, C1-C6 alkoxy, —
O-phenyl, —
CO—
OH, —
CO—
O—
(C1-C4 alkyl), and NR1-aR1-b;
or —
H. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)
- (CH2)n1—
Specification